Kimberly-Clark's $40 Billion Bid for Tylenol Maker Sparks Selloff, Trader Opportunity

Kimberly-Clark Corp.’s $40 billion plan to buy embattled Tylenol maker Kenvue Inc. sent its investors running for the exits — so much so, that some market specialists now see an opportunity for traders to step in and set themselves up for a potentially juicy reward.

The consumer health giant announced a cash-and-stock deal early Monday to buy Kenvue, whose headache remedy Tylenol has been targeted as unsafe by the Trump Administration. Terms implied total consideration of about $21 per share for the company, based on Friday’s close.